Biogen’s Lecanemab launched in China to treat Alzheimer’s Disease

The company states: “Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI”, generic name: lecanemab, has been launched in China. LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. Eisai estimates there will be 17 million patients with MCI or mild dementia due to AD (collectively referred to as early AD) in China in 2024, which is expected to increase as the population ages. Eisai is distributing the product in China and conducting information provision activities through specialized Medical Representatives, while also working to build a unique early AD diagnosis and treatment pathway that combines online and offline services. In collaboration with commercial health insurance companies, private health checkups, and nursing homes, Eisai will widely provide disease awareness and pre-screening opportunities and encourage high-risk individuals to visit specialized hospitals early or refer them to “Yin Fa Tong,”** an online health platform for the elderly that is focused on dementia, developed in a joint venture with JD Health.”